341 related articles for article (PubMed ID: 26934445)
41. Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide-Hoechst Conjugate Suppresses Tumor Growth
Liu K; Fang L; Sun H; Pan Z; Zhang J; Chen J; Shao X; Wang W; Tan Y; Ding Z; Ao L; Wu C; Liu X; Li H; Wang R; Su W; Li H
Mol Cancer Ther; 2018 May; 17(5):988-1002. PubMed ID: 29483218
[TBL] [Abstract][Full Text] [Related]
42. Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.
Bhuvaneswari R; Ng QF; Thong PS; Soo KC
Oncotarget; 2015 May; 6(15):13487-505. PubMed ID: 25918252
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
[TBL] [Abstract][Full Text] [Related]
44. Caffeic acid phenethyl ester upregulates N-myc downstream regulated gene 1 via ERK pathway to inhibit human oral cancer cell growth in vitro and in vivo.
Chung LC; Chiang KC; Feng TH; Chang KS; Chuang ST; Chen YJ; Tsui KH; Lee JC; Juang HH
Mol Nutr Food Res; 2017 Sep; 61(9):. PubMed ID: 28181403
[TBL] [Abstract][Full Text] [Related]
45. Cyclosporine A Suppresses the Malignant Progression of Oral Squamous Cell Carcinoma in vitro.
Gao L; Dong J; Zhang N; Le Z; Ren W; Li S; Li F; Song J; Wang Q; Dou Z; Park SY; Zhi K
Anticancer Agents Med Chem; 2019; 19(2):248-255. PubMed ID: 30378503
[TBL] [Abstract][Full Text] [Related]
46. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
[TBL] [Abstract][Full Text] [Related]
47. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
[TBL] [Abstract][Full Text] [Related]
48. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma.
Luo Q; Hu D; Hu S; Yan M; Sun Z; Chen F
BMC Cancer; 2012 Nov; 12():517. PubMed ID: 23151022
[TBL] [Abstract][Full Text] [Related]
49. Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.
Ritter A; Friemel A; Kreis NN; Louwen F; Yuan J
Oncotarget; 2016 Dec; 7(51):84271-84285. PubMed ID: 27713178
[TBL] [Abstract][Full Text] [Related]
50. Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.
Tyagi S; Bhui K; Singh R; Singh M; Raisuddin S; Shukla Y
Biochem Pharmacol; 2010 Nov; 80(9):1326-34. PubMed ID: 20655883
[TBL] [Abstract][Full Text] [Related]
51. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
52. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
[TBL] [Abstract][Full Text] [Related]
53. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.
Wang ZX; Xue D; Liu ZL; Lu BB; Bian HB; Pan X; Yin YM
Int J Biochem Cell Biol; 2012 Jan; 44(1):200-10. PubMed ID: 22064247
[TBL] [Abstract][Full Text] [Related]
54. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
Kreis NN; Louwen F; Zimmer B; Yuan J
Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
[TBL] [Abstract][Full Text] [Related]
55. The in vitro and in vivo antitumor effects of clotrimazole on oral squamous cell carcinoma.
Wang J; Jia L; Kuang Z; Wu T; Hong Y; Chen X; Leung WK; Xia J; Cheng B
PLoS One; 2014; 9(6):e98885. PubMed ID: 24892421
[TBL] [Abstract][Full Text] [Related]
56. Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma.
Park J; Kim HJ; Kim KR; Lee SK; Kim H; Park KK; Chung WY
Oncotarget; 2017 Feb; 8(6):9079-9092. PubMed ID: 28030842
[TBL] [Abstract][Full Text] [Related]
57. Down-regulation of Akt by methanol extracts of Impatiens balsamina L. promotes apoptosis in human oral squamous cell carcinoma cell lines.
Shin JA; Ryu MH; Kwon KH; Choi B; Cho SD
J Oral Pathol Med; 2015 Jul; 44(6):420-8. PubMed ID: 25212570
[TBL] [Abstract][Full Text] [Related]
58. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells.
Grinshtein N; Datti A; Fujitani M; Uehling D; Prakesch M; Isaac M; Irwin MS; Wrana JL; Al-Awar R; Kaplan DR
Cancer Res; 2011 Feb; 71(4):1385-95. PubMed ID: 21303981
[TBL] [Abstract][Full Text] [Related]
59. MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression.
Cai Z; Hao XY; Liu FX
Arch Oral Biol; 2018 May; 89():20-25. PubMed ID: 29407635
[TBL] [Abstract][Full Text] [Related]
60. PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase.
Inoue M; Yoshimura M; Kobayashi M; Morinibu A; Itasaka S; Hiraoka M; Harada H
Sci Rep; 2015 Oct; 5():15666. PubMed ID: 26503893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
